-
Xi Hao, CFO of Cinda Bio: Accelerating innovation and evolution, striving to become a new force in the global pharmaceutical market
Time of Update: 2021-04-18
Three new drugs were launched, four products were commercialized, and PD-1 performance doubled; losses narrowed by more than 40%, and overseas presence deepened. . . With the disclosure of the 2020 f
-
Why can't I buy the medicine that is "soul bargaining" in the medical insurance in the hospital?
Time of Update: 2021-04-18
Price reduction will not become the leading direction for drugs to enter the hospital's selection of drug catalogs Zhao Bin, deputy director of the Department of Pharmacy of Peking Union Medical College Hospital, said at the meeting that when drugs enter a hospital’s catalog, they must first meet clinical treatment needs.
-
57 large varieties, the results of collective procurement announced (list attached)
Time of Update: 2021-04-18
Medical Network News on April 12 The results of 57 large varieties to be selected are announced On April 8, the Joint Procurement Office of Guangxi Pharmaceutical Group issued the "Announcement on the Proposed Selection Results of the Sixth Batch of Guangxi Pharmaceutical Group Procurement (Second Batch)" and announced the proposed selection of 57 product regulations and hundreds of companies.
-
Yiling Pharmaceutical's Aniprofen Injection Formally Started Phase III Clinical Trial
Time of Update: 2021-04-18
On April 13, Yiling Pharmaceutical issued an announcement that the company's Phase III clinical trial plan for the company's 1.
From April 2019 to June 2020, the Phase II clinical trial was completed in 8 centers including the Third Xiangya Hospital of Central South University.
-
Hainan Free Trade Port relaxes drug market access to prescription drug online sales policy
Time of Update: 2021-04-18
(Leading units: National Health Commission, National Food and Drug Administration, National Development and Reform Commission are responsible according to the division of responsibilities; Participating units: National Medical Insurance Bureau, China Banking Regulatory Commission, State Administration of Traditional Chinese Medicine) (2) Support the innovative development of Hainan's localized high-end medical equipment.
-
Gilead's Trop-2 antibody conjugate drug gains second indication
Time of Update: 2021-04-18
S. FDA has accelerated the approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand its scope of use for the treatment of locally advanced or metastatic urothelium Cancer patients.
-
Renfu Pharmaceutical Memantine Hydrochloride Sustained-Release Capsules Received U.S. FDA Approval Number
Time of Update: 2021-04-18
On April 7, Renfu Medicine issued an announcement stating that its holding subsidiary, Yichang Renfu, had recently received an approval number from the US FDA for memantine hydrochloride sustained-release capsules.
According to statistics from IQVIA, the total sales of the drug in the US market in 2020 will be approximately 61 million U.
-
Huahai will win the first blockbuster imitating the original research drug company to monopolize the market and break the situation
Time of Update: 2021-04-18
Figure 2: Sales of Topiramate Tablets Source: Mi Nei. com, China's public medical institutions terminal competition pattern According to data from Menet.
Figure 2: Sales of Topiramate Tablets Source: Mi Nei. com, China's public medical institutions terminal competition pattern According to data from Menet.
-
The market shrank by 48.3 billion!
Time of Update: 2021-04-18
Whether to enter or not to enter, pharmaceutical companies are suffering The state implements a mass procurement policy with the goal of ensuring the sales of bid-winning companies, reducing sales links, and guaranteeing corporate profits.
-
Junshi Biologics JS007 injection clinical trial application accepted
Time of Update: 2021-04-18
JS007 is a recombinant humanized anti-CTLA-4 monoclonal antibody injection independently developed by Junshi Biotechnology, which is mainly used for the treatment of advanced malignant tumors.
The anti-tumor effect of the drug, and was approved for the treatment of advanced melanoma.
-
Subcutaneous RNAi therapy ALN-AGT Phase 1 clinical trial results are positive
Time of Update: 2021-04-18
Retrieved April 11, 2021, from /20210411005027/en[2] Safety, Pharmacodynamics, and Blood Pressure Effects of ALN-AGT, an RNA Interference Therapeutic Targeting Angiotensinogen, in a Randomized Single Ascending Dose Study of Hypertensive Adults.
Retrieved April 11, 2021, from /wp-content/uploads/2021/04/Safety-Pharmacodynamics-and-Blood-Pressure-Effects-of-ALN-AGT-an-RNA-Interference-Therapeutic-Targeting-Angiotensinogen-in-a-Randomized-Single-Ascending -Dose-Study-of-Hypertensive-Adults.
-
Break out on weekends!
Time of Update: 2021-04-18
On the afternoon of April 11, the official website of the State Supervision Commission of the Central Commission for Discipline Inspection issued a notice: Dai Longyong, the legal representative of Jiangxi Yongchang Pharmaceutical Co.
The official WeChat account of Jiangxi Provincial Commission for Discipline Inspection and Supervision, "Incorruption Jiangxi" also released the news today.
-
Special rectification of drug online sales is coming!
Time of Update: 2021-04-18
According to the arrangements, Shanxi will focus on safety net sales of the drug quality and safety, according to the characteristics of Internet sales of drugs, for key areas, focusing on business , never obtaining the qualification to carry out the problem of drugs Internet sales, drug sales net sellers of illegal drugs through a network problem , Three dimensions, including the performance of third-party platforms for online transaction services, continued to carry out special rectifications in depth.
-
AstraZeneca launches next-generation PARP inhibitors to continue Lynparza's success
Time of Update: 2021-04-18
AstraZeneca hopes that AZD5305 will be a successful follow-up product to Lynparza and provide a wider range of combination treatment options and earlier treatments because of its higher specificity and the potential to reduce safety risks.
-
Kelun Class 1 new drug hits 2 billion injections, the first four major products that have been reviewed and will be approved
Time of Update: 2021-04-18
The clinical application of KL590586 Capsules, a new class 1 drug, has been accepted by CDE, Moxifloxacin Hydrochloride Eye Drops, Propofol Fumarate, Tenofo The registration status of four generic drugs including Wei tablets, ticagrelor tablets and ropivacaine hydrochloride injection has been changed to "under approval" and is expected to be approved in the near future.
-
The price of 32 product regulations is lowered, Qilu, Chia Tai Tianqing, Eli Lilly and other well-known drugs are listed
Time of Update: 2021-04-18
On April 6, the Jiangsu Provincial Public Resources Trading Center issued a notice on adjusting the prices of some medicines.
The notice shows that the price of medicines for 32 product regulations has been lowered.
The specific price adjustments are as follows:
-
Summary of U.S. oral drug recalls in 2020
Time of Update: 2021-04-18
Also in May 2020, when the FDA detected a batch of products with NDMA content above the acceptable limit, Apotex voluntarily recalled its metformin hydrochloride extended-release tablets 500 mg.
-
Frequent adverse reactions after entering AstraZeneca, Johnson & Johnson vaccine is also thrombosis?
Time of Update: 2021-04-18
It is understood that the European Medicines Agency (EMA) issued an announcement on the 9th that 4 cases of abnormal thrombosis accompanied by thrombocytopenia were found among the vaccinators of Johnson & Johnson vaccine, and 1 of them died as a result.
-
Behind Ali's 18.2 billion huge fine, pharmaceutical anti-monopoly forces the entire industry to comply with regulations!
Time of Update: 2021-04-18
877 million yuan and 152,600 yuan respectively by the National Development and Reform Commission for illegally controlling the raw material of promethazine hydrochloride and driving up prices, causing related pharmaceutical companies to suspend production This is also the first fine issued by China for the monopoly of APIs.
-
The first imitation of tens of billions of blockbuster varieties is declared for listing, and the market is fierce
Time of Update: 2021-04-18
. Medical Network News on April 13 Ten billion market, the first imitation is nearly Recently, CDE's official website showed that Simcere's application for the listing of Ibrutinib capsules was officially accepted by the State Food and Drug Administration, becoming the first generic drug of Ibrutinib submitted for marketing in China, and it is expected to realize the first imitation.
